Our team recently attended two leading forums focused on the future of MASH research and treatment: the 2026 Paris MASH Meeting and the 10th MASH Drug Development Summit in Boston. Together, the conferences brought perspectives from clinical pract...
The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
A Science-Led CRO Partner for Complex Cardiometabolic Clinical Trials Cardiometabolic diseases rarely occur in isolation. Obesity, diabetes, cardiovascular disease, chronic kidney disease, lipid disorders, and metabolic liver disease share interc...
With obesity affecting more than one billion people globally and the market for obesity therapeutics projected to grow dramatically over the next decade, the stakes for sponsors have never been higher. Driven by breakthrough therapies, rapid marke...
Drawing on the experience and perspectives of Prof. Dr. Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, and Prof. Dr. Diederick (Rick) E. Grobbee, Chief Scientific Officer at P95 Julius Clinical, this article explores how sponsor...
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized TrialPatients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...
Comparing FIB-4 and MAF-5 for Advanced Fibrosis Screening in Primary Care Complete the form to access the poster and explore the preliminary GRIPonMASH findings.[gravityform id="19" title="false"]As the prevalence of MASLD and MASH contin...
Rescuing a Stalled Cardiovascular Outcomes Trial Through Targeted Operational Intervention When a Phase III cardiovascular outcomes trial (CVOT) faced significant enrollment delays and timeline risk, Julius Clinical was engaged to support and acc...
Executing a Complex Phase III Diabetes Cardiovascular Outcomes Trial in a High-Risk Population Cardiovascular outcomes trials (CVOTs) in type 2 diabetes present a unique combination of clinical, operational, and regulatory complexity, particularl...
"*" indicates required fields
"*" indicates required fields
